Evaluation of a Veterans Health Administration tool and policy to reduce patients’ risk of adverse events from opioid prescriptions

Not Applicable

Completed

• Conditions: Opioid use; Mental and Behavioural Disorders

• Registration Number: ISRCTN16012111
• Lead Sponsor: Department of Veterans Affairs Health Services Research & Development

Brief Summary

2019 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/30658658 protocol (added 21/01/2019) 2018 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/29950460 protocol (added 23/09/2019) 2020 Other publications in https://pubmed.ncbi.nlm.nih.gov/32576214/ strategy evaluation (added 25/06/2020) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35501628/ (added 03/05/2022) 2019 Other publications in https://doi.org/10.1080/08897077.2018.1540376 article commentary (added 15/06/2023) 2022 Results article in https://doi.org/10.1111/add.16110 secondary analysis (added 15/06/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-05-25
• Study Completion: 2019-09-30
• Last Update Posted: 26 June 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100000

Inclusion Criteria

1. Veterans Health Administration (VHA) patients with opioid prescription
2. Identified by STORM to have a risk of SAE in the top 10% of all VHA patients

Exclusion Criteria

Patients who are in palliative care or hospice care.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Opioid-related serious adverse events (SAEs) are determined using ICD9 and ICD10 codes using VA Corporate Data Warehouse in daily increments from baseline to 180 days.

Secondary Outcome Measures

Name	Time	Method
umber of case reviews and the number of completed risk mitigation strategies using VA Corporate Data Warehouse in daily increments from baseline to 180 days.